# Craig Parker

> Craig Parker is a Series B investor at Surrozen (San Francisco) backing Medical and Biopharma. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Surrozen](https://shizune.co/investors/profile/surrozen)
- Location: San Francisco, United States
- Total investments: 1
- Last investment: Jan 2002
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/craig-parker-603a044/

Craig Parker is a Series B investor at Surrozen in San Francisco focused on Medical and Biopharma. Craig Parker is the CEO at Surrozen.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 100% |
| Biopharma | 1 | 100% |
| Therapeutics | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Gryphon Therapeutics | Gryphon Therapeutics is a biopharmaceutical company focused on the development of performance-enhanced protein therapeutics. Its products combine chemically synthesized protein backbones with polyethylene glycols such as molecules to create potent medications. | $26M | Series B | Jan 28, 2002 |  |

1 of 1 investments shown.

## Co-investors
- [Forward Ventures](https://shizune.co/investors/profile/forward-ventures) — VC Fund, 1 deal together

## About Surrozen

VC Fund · South San Francisco, United States

Surrozen is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. Surrozen is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with potential application across multiple disease areas, including diseases of the intestine, liver, retina,cornea, lung, kidney, cochlea, skin, pancreas and central nervous system.

5 contacts available at Surrozen.

| Name | Title | Profile |
| --- | --- | --- |
| Craig Parker | Chief Executive Officer | https://shizune.co/investors/profile/craig-parker-aca2 |
| Craig Parker | Chief Executive Officer | https://shizune.co/investors/profile/craig-parker |
| Bill McLeod | Corporate Finance Consultant | https://shizune.co/investors/profile/bill-mcleod |
| Calvin Kuo | Co-Founder | https://shizune.co/investors/profile/calvin-kuo-c71a |
| Claudia Janda | Co-Founder and Senior Scientist | https://shizune.co/investors/profile/claudia-janda |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Craig Parker invest in?

Craig Parker invests primarily in Medical, Biopharma and Therapeutics startups, most often at Series B stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Craig Parker last invest?

The most recent investment recorded for Craig Parker closed in Jan 2002. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co